DGAP-News

RHÖN-KLINIKUM AG: Interim Report for the First Six Months of 2016:RHÖN-KLINIKUM AG Continues its Strong Growth - Strategic Focus on Network Medicine and Digitalisation

DGAP-News: RHÖN-KLINIKUM AG / Key word(s): Half Year Results
RHÖN-KLINIKUM AG: Interim Report for the First Six Months of
2016:RHÖN-KLINIKUM AG Continues its Strong Growth - Strategic Focus on
Network Medicine and Digitalisation

04.08.2016 / 06:59
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press Release

Interim Report for the First Six Months of 2016: RHÖN-KLINIKUM AG Continues
its Strong Growth - Strategic Focus on Network Medicine and Digitalisation

- 414,403 patients treated

- Revenues stand at Euro 590.6 million

- EBITDA in the amount of Euro 103.4 million includes dissolving
provisions of Euro 41 million

- Outlook for 2016 remains unchanged: Revenues between Euro 1.17 billion
and Euro 1.20 billion, EBITDA between Euro 155 million and Euro 165
million

Bad Neustadt / Saale, 4th August 2016

RHÖN-KLINIKUM AG continued its strong growth during the first six months of
the current financial year 2016. In the first half-year a total of 414,403
patients were treated in the corporate hospitals at the five different
sites. Revenues for the period from January up to and including June stood
at Euro 590.6 million. Earnings before interest, taxes, depreciation and
amortisation (EBITDA) amounted to Euro 103.4 million including provisions
of roughly Euro 41 million which had mainly been set aside for warranty
claims from the sales transaction with Fresenius/Helios and were dissolved
in the first six months of the financial year. The current financial
figures are therefore not directly comparable with those of previous years
due to these ongoing effects on the balance sheet.

Outlook

For financial year 2016 we expect revenues of Euro 1.17 billion to Euro
1.20 billion and earnings before interest, taxes, depreciation and
amortisation (EBITDA) of between Euro 155 million and Euro 165 million.
Positive and negative one-off effects, the size of which will be a low to
medium two-digit million figure, will continue to influence the corporate
results during this financial year as well and will partially cancel each
other out. They mainly result from handling the transaction with Fresenius/
Helios, the initial consolidation and integration of the municipal hospital
in Bad Neustadt, special budgets for innovation and e-health, unresolved
accounting issues and setting up a substantial diagnostic and out-patient
clinic at the university hospital in Marburg.

Further legislative restrictions which will temporarily have a negative
impact on the organic growth of the Company are currently to be expected in